Trevi Therapeutics, Inc. (TRVI) Research

Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the advancement and commercialization of Haduvio, a potential treatment for debilitating neurologically mediated conditions. This orally administered, extended-release formulation of nalbuphine is currently undergoing Phase IIb/III clinical trials for chronic pruritus (severe itching) and persistent cough experienced by patients with idiopathic pulmonary fibrosis. Trevi Therapeutics also possesses a licensing agreement with Endo Pharmaceuticals Inc., granting it the rights to develop and market products containing nalbuphine hydrochloride in various formulations. Established in 2011, the company maintains its corporate headquarters in New Haven, Connecticut.

Market snapshot

Symbol
TRVI
Price
$17.21
Day change
+5.13%
Market cap
$2.4B
P/E ratio
-54.94x
52-week range
5.41-17.61
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 2 months
Analyst price target
$25.00

Recent news

  • What's Going On With Trevi Therapeutics Stock?

    Trevi Therapeutics, Inc. (NASDAQ: TRVI) shares are trading higher after the company announced the pricing of its $150 million offering of 11.6 million shares at $13 per share.

Peer companies

  • Ardelyx, Inc. (ARDX)
  • Novavax, Inc. (NVAX)
  • ORIC Pharmaceuticals, Inc. (ORIC)
  • Precigen, Inc. (PGEN)
  • Terns Pharmaceuticals, Inc. (TERN)
  • Tourmaline Bio, Inc. (TRML)
  • Upstream Bio, Inc. (UPB)
  • Wave Life Sciences Ltd. (WVE)

Recent insider activity

  • Mathers Edward T — A-Award (35000 shares) on 2026-06-03
  • Colangelo Dominick — A-Award (35000 shares) on 2026-06-03
  • Meeker David P — A-Award (35000 shares) on 2026-06-03
  • VANLENT ANNE — A-Award (35000 shares) on 2026-06-03
  • Heffernan Michael Thomas — A-Award (35000 shares) on 2026-06-03

Open Trevi Therapeutics, Inc. (TRVI) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.